Herbal mix and cancer drug join forces to fight fluid in lungs
NCT ID NCT07670338
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula or a placebo, along with bevacizumab injected into the chest after drainage. The goal is to see if the combination improves fluid control, breathing, and quality of life over 8 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Xuanyin Ning Formula (Chinese herbal granules) and bevacizumab (a cancer drug injected into the chest)
What this could lead to
If it works, this combination could offer a new way to better control fluid buildup in the chest, improving breathing and quality of life for people with advanced lung cancer.
What could go wrong
This is an early-stage trial with no phase listed, so results are uncertain. The herbal formula may not add benefit over standard care, and bevacizumab carries risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Tenth People's Hospital Chongming Branch
Shanghai, Shanghai Municipality, 202157, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, 453100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weifang Traditional Chinese Medicine Hospital 或 Weifang Traditional Chinese Hospital
Weifang, Shandong, 261041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wuhan First Hospital
Wuhan, Hebei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, 200437, China
Contact Phone: •••-•••-•••• Email: •••••@•••••